Bristol Myers Squibb Beats Expectations

This is a news story, published by CNBC, that relates primarily to Eliquis news.

Eliquis news

For more Eliquis news, you can click here:

more Eliquis news

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

CNBC news

For more news from CNBC, you can click here:

more news from CNBC

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

Bristol Myers shares

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Bristol Myers news, earnings guidance news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

Bristol Myers Squibb

CNBC

•

Bristol Myers Squibb tops earnings estimates and hikes outlook, helped by Eliquis and new drugs

Summary

Nutrition label

85% Informative

Bristol Myers Squibb on Thursday reported third-quarter earnings and revenue that blew past Wall Street's expectations thanks to its blockbuster blood thinner Eliquis and a portfolio of drugs it expects to deliver long-term growth.

The pharmaceutical giant also raised its full-year revenue and adjusted earnings forecast.

The results come as Bristol Myers moves to cut $1.5 billion in costs by 2025 .

VR Score

Informative language

Neutral language

Article tone

formal

Language

English

Language complexity

Offensive language

not offensive